Please type a plus sign (+) inside this box ->

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE nd to a collection of information unless it contains a valid OMB control number.

ere required to r Under the Paperwork Reduction Act of 1995, no pers Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

Complete if Known			
Application Number	10/790,260		
Filing Date	03-02-2004		
First Named Inventor	Pascal DESMAZEAU, et al		
Group Art Unit	1654		
Examiner Name	LUKTON, David		
Attorney Docket Number	ST98007 - US - CNT		

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.1	U.S. Patent D	Ocument Kind Code ² (if known)	Name of Patentes or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ΩD	2002/0132765		BACQUE, et al	09-19-2002	
	YK	6,541,451		BACQUE, et al	04-01-2003	
XX		6,569,854		ACHARD, et al	05-27-2003	
						
		<u> </u>				
			-			
					 	

				FORE	IGN PATENT DOCUMENT	rs		
Examiner Initials*	Cite		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	
	No.1	Office ³	Number ⁴	Kind Code ^s (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Τ°
		oxdot		_			·	Ш
							· · · · · · · · · · · · · · · · · · ·	1
lacksquare		\vdash				-		+
		 						+
						 		+
			······································			1	- ,-	\Box
لــــــا		$\bot \bot \bot$	<u> </u>	$-\Delta$				لــــــــــــــــــــــــــــــــــــــ

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the emount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 2 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ease type a plus sign (+) inside this box 🛶 🗸

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut	te for form 1449B/PT	·0		Complete If Known		
		-		Application Number	10/790,260	
INFO	DRMATIO	NE	ISCLOSURE	Filing Date	03-02-2004	
STA	TEMENT	RY	APPLICANT	First Named Inventor	Pascal DESMAZEAU, et al	
UIA			AI I LIOAIII	Group Art Unit	1654	
	(use as many	sheet	s as necessary)	Examiner Name	LUKTON, David	
Sheet	2	of	3	Attorney Docket Number	ST98007 - US - CNT	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
SI	و ا	ATKINSON G. et al., How To Show That Unicom Milk Is A Chronobiotic: The Reagression-to-the-Mean Statistical Artifact, Chronobiology International (2001, pp. 1041-1053, Volume 18, No. 6) Abstract Only							
		BEZEAU S. et al., Statistical Power And Effect Sizes Of Clinical Neuropsychology Research, Journal of Clinical Experimental Neuropsychology (2001, pp. 399-406, Volume 23, No. 3) Abtract Only							
		BOLTON S., Independence and Statistical Inference In Clinical Trial Designs: a Tutorial Review, Journal Clinical Pharmacology (1998, pp. 408-412, Volume 38, No. 5) Abstract Only							
		BRYANT TN, The Presentation Of Statistics, Pediatric Allergy Immunology (1998, pp. 108-115, Volume 9, No. 3) Abstract Only							
		CHUNG KC et al., The Prevalence Of Negative Studies With Inadequate Statistical Power. An Analysis Of The Plastic Surgery Literature, Plastic and Reconstructive Surgery (2002, pp. 1-6, Volume 109, No. 1) Abstract Only							
		DORIT AVRAHAMI et al., Effect of Multiple Aliphatic Amino Acids Substitutions on the Structure, Function, and Mode of Action of Diastereomeric Membrane Active Peptides, Biochemistry (2001, pp. 12591-12603, Volume 40)							
		ELISABETTA GAVINI et al., Synthesis and "in Vitro" Antimicrobial Properties of N-Oxide Derivatives Based on Tricyclic Indeno(2,1-c) pyridazine and Benzo(I) cinnoline systems, Arch. Pharm. Med. Chem. (2000, pp.341-346, Volume 333)							
Z Z		JOHN LUDBROOK, Statistics In Physiology And Pharmacology: A Slow And Erratic Learning Curve, Clinical And Experimental Pharmacology and Physiology (2001, pp. 488-492, Volume 28)							
X)	P. JUVVADI et al., Structure-activity studies of normal and retro pig cecropin-melittin hybrids, Journal of Peptide Research (1999, pp. 244-251, Volume 53)							
Examiner Signature		Date Considered 9-26-05							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a nius	sign (+) inside this box 🛶	
i lease type a plus	angir (+) maide one box	'

Sheet

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number.

Substitu	te for form 1449B/F	то		Co	mplete if Known
				Application Number	10/790,260
INF	ORMATIC)N C	ISCLOSURE	Filing Date	03-02-2004
STA	Substitute for form 1449B/PTO NFORMATION DISCLOSURI STATEMENT BY APPLICAN (use as many sheets as necessary)	APPLICANT	First Named Inventor	DESMAZEAU	
• • • • • • • • • • • • • • • • • • • •				Group Art Unit	1654
	(use as many	y sheet	s as necessary)	Examiner Name	LUKTON, David
heet	3	of	3	Attorney Docket Number	ST98007 - US - CNT

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		RONNIE WILLENHEIMER, Statistical Significance Versus Clinical Relevance in Cardiovascular Medicine, Progress in Cardiovascular Diseases (2001, pp. 155-167, Volume 44, No. 3)	
\rightarrow		RYOSUKE FUDOU et al., Haliangicin, a Novel Antifungal Metabolite Produced by a Marine Myxobacterium, The Journal of Antibiotics (2001, pp. 149-152, Volume 54, No. 2)	
SL	,	VERONIQUE BLANC et al., Cloning and Analysis of Structural Genes from Streptomyces pristinaespiralis Encoding Enzymes Involved in the Conversion of Pristinamycin II beta to Pristinamycin II a (PIIA): PIIA Synthase And NADH: Riboflavin 5'-Phosphate Oxidoreductase, Journal of Bacteriology (1995, pp. 5206-5214)	
Examiner Signature		Date Considered 9-26-05	`

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.